Yang YQ, Li N, Liu S, Yu YW. Uridine diphosphate-glucose 6-dehydrogenase-mediated glucuronidation and its emerging role in gut-liver immune regulation. World J Gastrointest Oncol 2025; 17(10): 110464 [PMID: 41114112 DOI: 10.4251/wjgo.v17.i10.110464]
Corresponding Author of This Article
Yong-Wei Yu, PhD, Department of Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. yuyongwei@zju.edu.cn
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Oct 15, 2025 (publication date) through Oct 25, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Yang YQ, Li N, Liu S, Yu YW. Uridine diphosphate-glucose 6-dehydrogenase-mediated glucuronidation and its emerging role in gut-liver immune regulation. World J Gastrointest Oncol 2025; 17(10): 110464 [PMID: 41114112 DOI: 10.4251/wjgo.v17.i10.110464]
World J Gastrointest Oncol. Oct 15, 2025; 17(10): 110464 Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.110464
Uridine diphosphate-glucose 6-dehydrogenase-mediated glucuronidation and its emerging role in gut-liver immune regulation
Ye-Qiu Yang, Ning Li, Shuai Liu, Yong-Wei Yu
Ye-Qiu Yang, Shuai Liu, Department of Cardiology, The First People’s Hospital of Jiashan, Jiaxing 314100, Zhejiang Province, China
Ning Li, Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Yong-Wei Yu, Department of Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Co-corresponding authors: Shuai Liu and Yong-Wei Yu.
Author contributions: Yang YQ and Li N wrote the manuscript; Yu YW and Liu S designed the study and revised the manuscript; All listed authors consent to the submission.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Wei Yu, PhD, Department of Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. yuyongwei@zju.edu.cn
Received: June 10, 2025 Revised: July 13, 2025 Accepted: August 14, 2025 Published online: October 15, 2025 Processing time: 129 Days and 22.5 Hours
Core Tip
Core Tip: Uridine diphosphate-glucose 6-dehydrogenase (UGDH), a key metabolic enzyme involved in glucuronidation, is increasingly recognized for its role in hepatocellular carcinoma progression. Recent studies have revealed that dysregulated UGDH contributes not only to metabolic reprogramming but also to immune suppression by disrupting bile acid detoxification and facilitating microbial translocation from the gut. This editorial highlights the dual function of UGDH as both a metabolic and immune modulator, and introduces a novel hypothesis that positions UGDH as a potential checkpoint within the gut-liver immune axis. Understanding this interplay could lead to new therapeutic strategies targeting metabolic-immune cross-talk in gastrointestinal oncology.
